62 -2 (88) 2026 - G.U. Sultanmuratova, S.A. Matyakubova - EFFECTIVENESS OF FERROUS SULFATE IN PREGNANT WOMEN WITH ANEMIA
EFFECTIVENESS OF FERROUS SULFATE IN PREGNANT WOMEN WITH ANEMIA
G.U. Sultanmuratova - Tashkent State Medical University
S.A. Matyakubova - Urgench State Medical Institute Uzbekistan, State Institution Branch of the Republican Specialized Scientific and Practical Medical Center for Maternal and Child Health of the Khorezm Region
Resume
Study objective: To evaluate the clinical efficacy of the antianemic drug ferrous sulfate in pregnant women with mild to moderate anemia. Materials and methods: This prospective study included 36 pregnant women: 20 patients with mild to moderate anemia (study group) and 16 healthy pregnant women (control group). All participants underwent a complete blood count, and ferritin, folate, and vitamin B₁₂ levels were determined using ELISA and ELISA. Pregnant women in the study group received Tardiferon at a dosage of 80 mg (one tablet once daily after meals) for 4 weeks, followed by monitoring of hematological and biochemical parameters.Results: The average hemoglobin level in the study group was 87 ± 12 g/L versus 120 ± 14.8 g/L in the control group (p < 0.05). Patients with anemia also showed decreased red blood cell count, MCH, ferritin, and folate levels, while vitamin B₁₂ levels were normal. After 4 weeks of therapy, hemoglobin levels increased by 8 g/L (p < 0.05), and ferritin by 27.1 ng/ml (p < 0.001). However, statistically significant differences from the control group remained, indicating the need for continued therapy for full recovery. Supplemental folic acid intake in patients with folic acid deficiency promoted accelerated normalization of these parameters.Conclusion: These data allow us to recommend the use of ferrous sulfate in the complex treatment of iron deficiency anemia in pregnant women, given its availability and positive clinical effect.
Keywords: pregnancy, anemia, ferrous sulfate, ferritin, reproductive age
First page
307
Last page
313
For citation:G.U. Sultanmuratova, S.A. Matyakubova - EFFECTIVENESS OF FERROUS SULFATE IN PREGNANT WOMEN WITH ANEMIA//New Day in Medicine 2(88)2026 307-313 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026
List of References
- Доброхотова Ю.Э., Маркова Э.А. Пероральная пролонгированная форма препарата железа для лечения железодефицитной анемии: клинический разбор и фармакоэкономическая оценка. РМЖ. Мать и дитя. 2020;3:1-7. DOI:10.32364/2618-8430-2020-3-2-88-94
- Тютюнник В.Л., Кан Н.Е., Михайлова О.И. Коррекция железодефицитной анемии у беременных. Акушерство и гинекология. 2018; 8:105-10.
- Adamson JW. Fauci AS. Kasper DL, et al. Iron deficiency and other hypoproliferative anaemias. In: Braunwald E, editor; Harrison's Principles of Internal Medicine.15th edition. Mc Graw Hill; 2001; 660–66 pp.
- Beris P, Maniatis A on behalf of the NATA working group on intravenous iron therapy (2007). Guidelines on intravenous iron supplementation in surgery and obstetrics/gynecology. TATM transfus Altern Transfus Med 9 (Suppl 1):9.
- Coad J, Conlon C. Iron deficiency in women: assessment, causes and consequences. Current opinion in clinical nutrition and metabolic care. 2011, 14, 625-634
- Friedman AJ et al. Iron deficiency anemia in women across the life span. Journal of women's health, 2012;21:1282-1289.
- Leary A, Barthe L, Clavel T, et al. Iron Pharmacokinetics in Women with Iron Deficiency Anaemia Following A Single Oral Dose of a Novel Formulation of Tardyferon (Prolonged Release Ferrous Sulphate). Drug Res (Stuttg). 2017;67(11):647-52. DOI:10.1055/s-0043-113636
- Lopes A., Cacoub P., Macdougall I. C., Peyrin-Biroulet L. Iron deficiency anaemia // Lancet. 2016;387(10021):907-916.
- Makrides M, Crowther CA, Gibson RA, Gibson RS, Skeaff CM (2003). Efficacy and tolerability of low-dose iron supplements during pregnancy: a randomised controlled trial. Am J Clin Nutr, 2003;78:145-153.
- Milman N (2006). Iron and pregnancy -- a delicate balance. Ann Hematol, 2006;85:559-565.
file
download